Opendata, web and dolomites

AML-VACCiN SIGNED

Clinical development of a dendritic-cell vaccine therapy for acute myeloid leukaemia

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 AML-VACCiN project word cloud

Explore the words cloud of the AML-VACCiN project. It provides you a very rough idea of what is the project "AML-VACCiN" about.

selective    leukaemia    assemble    clinical    safety    001    dcp    private    treating    close    proof    dc    vaccin    biomarker    personalised    efficacy    deadly    shelf    nine    gt    immune    line    myeloid    conditional    younger    disease    inducing    45    older    approval    medicinal    preclinical    patients    age    residual    toxic    vaccinate    powerful    risk    unmet    safe    immunotherapy    adults    institutes    scientists    orchestrated    reduce    forefront    profile    relapse    cell    internationally    renowned    innovative    area    patient    off    orphan    die    data    consolidation    treatment    85    children    acute    enrolment    standard    dendritic    public    rare    stage    companies    takes    designated    intended    action    eradicating    cured    medical    vaccine    aml    outcome    eradicate    iia    ing    irdirc    approximately    iib    minimal    representing    remission    status    shown    therapy    mrd    ultimately    induction    monitoring   

Project "AML-VACCiN" data sheet

The following table provides information about the project.

Coordinator
STICHTING VUMC 

Organization address
address: DE BOELELAAN 1117
city: AMSTERDAM
postcode: 1081 HV
website: www.vumc.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website http://www.amlvaccin.eu
 Total cost 8˙278˙716 €
 EC max contribution 6˙001˙482 € (72%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-PHC-2015-two-stage
 Funding Scheme RIA
 Starting year 2016
 Duration (year-month-day) from 2016-01-01   to  2020-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    STICHTING VUMC NL (AMSTERDAM) coordinator 364˙640.00
2    BIONTECH INNOVATIVE MANUFACTURING SERVICES GMBH DE (IDAR OBERSTEIN) participant 2˙057˙500.00
3    IMMATICS BIOTECHNOLOGIES GMBH DE (TUEBINGEN) participant 1˙300˙650.00
4    LINICAL ACCELOVANCE EUROPE BV NL ('S-HERTOGENBOSCH) participant 1˙022˙313.00
5    DCPRIME BV NL (LEIDEN) participant 495˙150.00
6    UNIVERSITETET I BERGEN NO (BERGEN) participant 184˙989.00
7    ACADEMISCH ZIEKENHUIS GRONINGEN NL (GRONINGEN) participant 82˙320.00
8    HELSE BERGEN HF*HAUKELAND UNIVERSITY HOSPITAL NO (BERGEN) participant 82˙320.00
9    HELSINGIN YLIOPISTO FI (HELSINGIN YLIOPISTO) participant 82˙320.00
10    TECHNISCHE UNIVERSITAET DRESDEN DE (DRESDEN) participant 82˙320.00
11    UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZ DE (Mainz) participant 82˙320.00
12    UNIVERSITATSKLINIKUM BONN DE (BONN) participant 82˙320.00
13    UPPSALA UNIVERSITET SE (UPPSALA) participant 82˙320.00
14    STICHTING VU NL (AMSTERDAM) participant 0.00

Map

 Project objective

Eradicating minimal residual disease (MRD) in patients with acute myeloid leukaemia (AML) is an area of high unmet medical need. AML is a deadly rare disease that affects both children and adults. Approximately 45% of younger AML patients who are treated will be cured, and in older patients (>60 years of age), 85% will relapse and die within 2 years.

Immunotherapy has great potential for treating MRD and dendritic cell (DC) therapy is at the forefront of immunotherapy. The AML-VACCiN consortium takes this to the next level through clinical development of a highly-innovative DC vaccine - DCP-001 - that can be produced off-the-shelf and has a powerful preclinical and clinical profile. The aim is to vaccinate AML patients that have been brought into remission through standard induction or consolidation therapy, and to eradicate MRD and effectively reduce the risk of relapse.

In a clinical Phase I/IIa study, the DCP-001 vaccine has already shown to be safe, non-toxic and capable of inducing an AML-targeted immune response. DCP-001 is designated as an orphan medicinal product in the EU.

The AML-VACCiN consortium will advance the clinical development of the vaccine from early-stage (current status) towards proof of concept for safety and efficacy in a Phase IIb clinical study (intended outcome of this project). In addition, a biomarker program will be developed that enables more effective treatment monitoring, selective patient enrolment in future studies and ultimately personalised AML treatment. The deliverables resulting from this project can be used to assemble a data package to apply for conditional approval in Europe.

AML-VACCiN is the orchestrated action of three innovative companies and internationally renowned top medical scientists representing nine European medical institutes. In line with the IRDiRC objectives, this public-private consortium can bring a powerful AML-vaccine very close to clinical practice.

 Deliverables

List of deliverables.
Document providing the logo and templates for a uniform corporate look Other 2020-04-23 02:18:27
Communication and dissemination plan Documents, reports 2020-04-23 02:18:27

Take a look to the deliverables list in detail:  detailed list of AML-VACCiN deliverables.

 Publications

year authors and title journal last update
List of publications.
2018 Arjan A. van de Loosdrecht, Sandra van Wetering, Saskia J. A. M. Santegoets, Satwinder Kaur Singh, Corien M. Eeltink, Yvonne den Hartog, Malika Koppes, Jorn Kaspers, Gert J. Ossenkoppele, Ada M. Kruisbeek, Tanja D. de Gruijl
A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia
published pages: 1505-1518, ISSN: 0340-7004, DOI: 10.1007/s00262-018-2198-9
Cancer Immunology, Immunotherapy 67/10 2020-04-23

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "AML-VACCIN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "AML-VACCIN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More